###begin article-title 0
###xml 56 61 <span type="species:ncbi:9606">human</span>
XRCC1 is required for DNA single-strand break repair in human cells
###end article-title 0
###begin p 1
###xml 606 642 606 642 <email xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">journals.permissions@oupjournals.org</email>
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article for non-commercial purposes provided that: the original authorship is properly and fully attributed; the Journal and Oxford University Press are attributed as the original place of publication with the correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oupjournals.org
###end p 1
###begin p 2
###xml 149 154 149 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 165 170 <span type="species:ncbi:10090">mouse</span>
###xml 346 351 <span type="species:ncbi:9606">human</span>
###xml 455 460 <span type="species:ncbi:9606">human</span>
###xml 571 576 <span type="species:ncbi:9606">human</span>
###xml 680 685 <span type="species:ncbi:302767">comet</span>
###xml 1154 1159 <span type="species:ncbi:9606">human</span>
The X-ray repair cross complementing 1 (XRCC1) protein is required for viability and efficient repair of DNA single-strand breaks (SSBs) in rodents. XRCC1-deficient mouse or hamster cells are hypersensitive to DNA damaging agents generating SSBs and display genetic instability after such DNA damage. The presence of certain polymorphisms in the human XRCC1 gene has been associated with altered cancer risk, but the role of XRCC1 in SSB repair (SSBR) in human cells is poorly defined. To elucidate this role, we used RNA interference to modulate XRCC1 protein levels in human cell lines. A reduction in XRCC1 protein levels resulted in decreased SSBR capacity as measured by the comet assay and intracellular NAD(P)H levels, hypersensitivity to the cell killing effects of the DNA damaging agents methyl methanesulfonate (MMS), hydrogen peroxide and ionizing radiation and enhanced formation of micronuclei following exposure to MMS. Lowered XRCC1 protein levels were also associated with a significant delay in S-phase progression after exposure to MMS. These data clearly demonstrate that XRCC1 is required for efficient SSBR and genomic stability in human cells.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 196 197 196 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
DNA single-strand breaks (SSBs) are among the most frequent DNA lesions, arising directly from damage to the deoxyribose moieties or indirectly as intermediates of DNA base excision repair (BER) (1-3). Left unrepaired, SSBs are a major threat to genetic stability and cell survival, accelerating mutation rates and increasing levels of chromosomal aberrations (4-7). The pathways for SSB repair (SSBR) in mammalian cells involve a number of co-ordinated, sequential reactions responsible for damage detection, end processing, gap filling and ligation. In the case of the short-patch pathway of BER for example, a damaged base is recognized and removed by a damage-specific glycosylase, thus creating an abasic site whose 5' phosphodiester bond is cut by apurinic/apyridinic endonuclease 1 (APE1). Subsequently, DNA polymerase beta adds 1 nt to the 3'-OH end of the cleaved abasic site and excises the base-free sugar phosphate residue. Finally, this ligatable nick is sealed by DNA ligase IIIalpha.
###end p 4
###begin p 5
###xml 535 536 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 537 539 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 666 668 659 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 669 671 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
Substantial evidence indicates an important role for X-ray repair cross complementing 1 (XRCC1) in SSBR and BER. Apparently devoid of any enzymatic activity, this protein is thought to act as a scaffolding protein for other repair factors. XRCC1 has been shown to physically interact with several enzymes known to be involved in the repair of SSBs, including DNA ligase IIIalpha, DNA polymerase beta, APE1, polynucleotide kinase/phosphatase, poly(ADP-ribose) polymerases 1 and 2 (PARP-1 and 2) and 8-oxoguanine DNA glycosylase (OGG1) (8-14). Recently, XRCC1 has also been reported to be associated with aprataxin, the protein mutated in Ataxia-oculomotor apraxia 1 (15,16).
###end p 5
###begin p 6
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 273 278 273 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 481 482 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 509 514 509 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 543 546 543 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 565 570 565 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 716 718 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
###xml 547 551 <span type="species:ncbi:10090">mice</span>
###xml 820 825 <span type="species:ncbi:10090">mouse</span>
XRCC1-deficiency in mice results in embryonic lethality (17). Mutant mouse or CHO cells with no functional XRCC1 protein are hypersensitive to a broad range of DNA damage induced by alkylating agents, reactive oxygen species or ionizing radiation (17-19). SSB rejoining in XRCC1-deficient rodent cells is severely impaired, indicating a defect in DNA repair. Additionally, these cells display increased rates of spontaneous sister-chromatid exchange and chromosomal aberrations (4,5,17,19-21). Interestingly, XRCC1 transgene complemented XRCC1-/- mice that express XRCC1 at highly reduced levels, develop apparently normally and fibroblasts from these animals exhibit almost normal sensitivity to alkylating agents (22). Based on these experiments, it was concluded that XRCC1 is not the rate-limiting factor in SSBR in mouse cells.
###end p 6
###begin p 7
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
Considerable evidence from CHO cells suggests that the hypersensitivity of XRCC1 mutant cells to genotoxins reflect perturbations of DNA replication. This is probably due to a greater number or the longer persistence of unrepaired SSBs encountered by the replication fork or to a deficiency in replication origin firing (4,23,24). The observations that XRCC1 foci increases during S-phase and co-localize with PCNA at replication sites underlines the importance of XRCC1 at this stage of the cell cycle (25-27).
###end p 7
###begin p 8
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 239 246 239 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 331 336 331 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 339 341 339 341 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 6 11 <span type="species:ncbi:9606">human</span>
###xml 114 119 <span type="species:ncbi:9606">human</span>
###xml 299 304 <span type="species:ncbi:9606">human</span>
As no human cell line lacking XRCC1 has been identified, few functional studies have investigated the role of the human XRCC1 protein in a cellular context. In HeLa cells, XRCC1 is recruited to laser irradiation-induced sites of SSB (28). In vivo evidence that XRCC1 is indeed necessary for SSBR in human cells was reported by Luo et al. (16), who downregulated XRCC1 expression by RNA interference (RNAi) and found that partial loss of XRCC1 renders HeLa cells sensitive to methyl methanesulfonate (MMS).
###end p 8
###begin p 9
###xml 114 119 114 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 374 376 374 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 564 569 <span type="species:ncbi:9606">human</span>
###xml 695 700 <span type="species:ncbi:9606">human</span>
In the last few years, many molecular epidemiological studies have investigated the possible associations between XRCC1 polymorphisms and altered cancer risk. The presence of certain polymorphisms seem to be associated with either increased or decreased cancer susceptibility, depending on the type of cancer and the levels of environmental exposure to DNA damaging agents (29-36). These results suggest that the variant alleles may modify XRCC1's function. As a first step to investigate this phenomenon, we have used an RNAi approach to modulate XRCC1 levels in human breast cancer cell lines and report here that XRRC1 is necessary for survival, efficient DNA repair and genomic stability in human cells after DNA damage.
###end p 9
###begin title 10
MATERIALS AND METHODS
###end title 10
###begin title 11
Cells and cell culture
###end title 11
###begin p 12
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 332 336 <span type="species:ncbi:9913">calf</span>
Human breast cancer cell lines BT20 and MDA-MB-453 were obtained from the American Tissue Culture collection (ATCC HTB-19 and HTB-131, respectively). MDA-MB-549 was a gift from Alain Puisieux (Centre Leon Berard, Lyon, France). They were cultured in DMEM (Gibco, Invitrogen Corporation) supplemented with 10% heat-inactivated fetal calf serum, 100 U/ml penicillin and 100 mug/ml streptomycin.
###end p 12
###begin title 13
RNA interference
###end title 13
###begin p 14
###xml 159 164 159 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
The short interfering RNA (siRNA) duplexes were designed and synthesized by Eurogentec. The sequences were as follows: 5'-AGGGAAGAGGAAGUUGGAU-3' to target the XRCC1 transcript and 5'-AAACCCGAUAAUAACGUUGCG-3' (scrambled control, containing the nucleotides of a region of the XRCC1 transcript in a random order). Cells were transfected using Oligofectamine (Invitrogen) according to the manufacturer's protocol, with a final oligonucleotide concentration of 100 nM. If not otherwise stated, cells were split after 48 h and treated with indicated concentrations of DNA damaging agents 72 h after the start of transfection.
###end p 14
###begin title 15
RT-PCR and immunoblotting
###end title 15
###begin p 16
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 553 558 534 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 657 662 638 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
In order to monitor the modulation of XRCC1 mRNA levels, a quantitative RT-PCR approach was used. Total RNA was extracted using Trizol (Invitrogen) according to the manufacturer's protocol and cDNA was prepared with 1 mug total RNA using the iScript cDNA Synthesis kit (Bio-Rad). Real-time PCR was run in a Stratagene Mx 3000P system and consisted of a 10 min initial denaturation at 95degreesC, followed by 40 cycles of 30 s at 95degreesC and 60 s at 60degreesC. The reactions were prepared with TaqMan Master Mix (Applied Biosystems). Assay-on-demand GAPDH control reagent (Applied Biosystems) was used to quantify the expression of a reference gene. The XRCC1-specific primers and probe were designed using the Primer Express software (Applied Biosystems) and were as follows: 5'-GGGACCGGGTCAAAATTGTT-3', 5'-ACCGTACAAAACTCAAGCCAAAG-3' and 5'-6FAM-AGCCCTACAGCAAGGA-MGB-3'.
###end p 16
###begin p 17
###xml 80 82 80 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
Protein extraction and immunoblotting were carried out as described previously (37), with 30 mug of protein being loaded per lane. The membranes were incubated with antibodies to XRCC1 (R&D Systems; 1:1250 dilution), PARP-1 (Alexis Biochemicals; 1:5000 dilution), ligase III (abcam; 1:1000 dilution), APE1 (BD Biosciences; 1:250 dilution) and actin (ICN Biomedicals; 1:5000 dilution). The antigen-antibody complexes were detected by ECL western blotting detection reagent (Amersham). Protein levels were quantified using the Fluor-S MultiImager (Bio-Rad) and the Quantity One 4.2.1 software (Bio-Rad).
###end p 17
###begin title 18
Survival curves and determination of intracellular NAD(P)H
###end title 18
###begin p 19
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 144 145 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 519 520 513 514 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
The siRNA-transfected and control cells were split and plated into 96-well dishes (3000-5000 cells/well). The next day, they were exposed to H2O2 for 40 min or MMS for 1 h in complete medium, at 37degreesC. After washing with phosphate-buffered saline (PBS), cells were incubated for 3 days in drug-free medium. Survival was assayed using the CellTiter Aqueous One Solution Cell Proliferation Assay (Promega) according to the manufacturer's protocol. To measure survival after exposure to ionizing radiation, 0.5-1 x 105 cells were plated into T25 flasks and irradiated the following day. They were further incubated for 3-5 days and survival was assessed by Trypan Blue exclusion. All measurements were done in triplicate and experiments repeated at least twice.
###end p 19
###begin p 20
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
Depletion of intracellular NAD(P)H was monitored as described (38) using CCK-8 solution (Dojindo Molecular Technology). Briefly, transfected or mock-transfected cells were split and seeded into 96-well plates. The next day, CCK-8 was added and cells were treated with MMS in the presence or absence of 10 mM 3-aminobenzamide (3-AB) (Sigma). Absorbance at 450 and 600 nm was measured 4 h after the start of the treatment. Measurements were done in triplicate.
###end p 20
###begin title 21
Micronucleus assay
###end title 21
###begin p 22
###xml 234 236 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
Following MMS treatment for 1 h, cells were washed with PBS and reincubated in normal medium containing 3 mug/ml cytochalasin B (Sigma) for 48 h before harvesting. Fixing, staining and scoring was carried out as described previously (39). A total of 400 binucleated cells per slide were scored for each transfection condition. Micronuclei were assessed in two independent experiments.
###end p 22
###begin title 23
###xml 0 5 <span type="species:ncbi:302767">Comet</span>
Comet assay
###end title 23
###begin p 24
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 837 839 830 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 1309 1311 1302 1304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 89 94 <span type="species:ncbi:302767">comet</span>
###xml 818 823 <span type="species:ncbi:302767">Comet</span>
###xml 920 925 <span type="species:ncbi:302767">Comet</span>
DNA damage was evaluated using the alkaline (pH > 13) single-cell gel electrophoresis or comet assay (40,41). Transfected cells were MMS-treated, washed and reincubated in normal medium for 3 h before processing. Harvested cells (1 x 105) were mixed with 0.5% low melting agarose (Bio Whittaker Molecular Applications) and layered onto agarose-coated slides. Slides were then submerged into lysis buffer [2.5 M NaCl, 100 mM EDTA, 10 mM Tris (pH 10.0) and 1% Triton X-100] overnight at 4degreesC. After lysis, slides were incubated for 1 h in electrophoresis buffer (300 mM NaOH and 1 mM EDTA, pH 13). After electrophoresis (1 h, 25 V, 300 mA), slides were neutralized with 0.4 M Tris, pH 7.5, for 30 min, placed into 100% ethanol and then air-dried. Slides were stained with 2 mug/ml ethidium bromide (Sigma). Average Comet Tail Moment (40) was scored (50 cells/slide) under an Axioplan2 Microscope (Zeiss) by using the Comet Imager 1.2.10 software (MetaSystems). All measurements were done on duplicate slides. Repair was quantified by calculating the percentage of MMS-induced strand breakage remaining after 3 h incubation in drug-free medium with the equation [(mean tail moment after repair - mean tail moment untreated cells)/(mean tail moment initial damage - mean tail moment untreated cells)] x 100 (27).
###end p 24
###begin title 25
Flow cytometric analysis
###end title 25
###begin p 26
Cells were MMS-treated for 1 h and reincubated in normal medium. At the indicated time points, they were processed using the CycleTest PLUS DNA reagent Kit (Becton Dickinson). Analysis was carried out in a Facscalibur (Becton Dickinson), cell-cycle distribution was assessed using the ModFit LT 2.0 software (Verity Software House).
###end p 26
###begin title 27
RESULTS
###end title 27
###begin title 28
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 16 21 <span type="species:ncbi:9606">human</span>
XRCC1-deficient human cell lines are hypersensitive to DNA damaging agents
###end title 28
###begin p 29
###xml 40 45 40 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 316 321 304 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 385 394 373 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1A</xref>
###xml 517 526 505 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1A</xref>
###xml 66 71 <span type="species:ncbi:9606">human</span>
We adopted an RNAi approach to modulate XRCC1 expression in three human breast cancer cell lines, BT20, MDA-MB-453 and MDA-MB-549. Seventy-two hours after the start of transfection, quantitative RT-PCR revealed a reduction of XRCC1 mRNA levels of approximately80% (in MDA-MB-549 and BT20) and 65% (in MDA-MB-453) in XRCC1 siRNA-transfected cells compared with levels in control cells (Figure 1A, upper panels). Western blotting confirmed these results and showed that mRNA and protein levels were closely correlated (Figure 1A, lower panels).
###end p 29
###begin p 30
###xml 156 158 148 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
###xml 159 161 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 248 253 236 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 331 340 319 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figure 1B</xref>
###xml 417 422 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 530 535 518 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 596 598 584 586 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 264 269 <span type="species:ncbi:9606">human</span>
In CHO cells, XRCC1 has been shown to form a complex with DNA ligase IIIalpha (Lig IIIalpha) and to act as an important stabilizing factor of this protein (42,43). In agreement with these findings, the level of DNA Lig IIIalpha protein detected in XRCC1-deficient human cells was significantly reduced compared with control cells (Figure 1B). In contrast, no difference in APE1 protein levels in cells with modulated XRCC1 expression was found 72 h after the start of transfection. This result is in contrast with observations in XRCC1 mutant CHO cells, where upregulated APE1 levels were noted (11).
###end p 30
###begin p 31
###xml 179 187 179 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Figure 2</xref>
###xml 358 363 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
In order to examine the biological consequences of reduced XRCC1 levels, we measured cell survival after induction of DNA damage by MMS, hydrogen peroxide and ionizing radiation (Figure 2). In all three lines, decreased XRCC1 levels were associated with increased sensitivity to the three genotoxins tested. The relative increase in sensitivity was lower in XRCC1 siRNA-transfected MDA-MB-453 cells as compared with the other two cell lines tested. For example, MMS-sensitivity of siRNA-transfected MDA-MB-549 and BT20 cells increases 1.8-fold (LD20), while the sensitivity of MDA-MB-453 cells with reduced XRCC1 increases 1.4-fold compared with their control counterparts. This probably reflects the fact that in MDA-MB-453 cells, RNAi is the least effective and approximately35% of XRCC1 protein is still present after transfection.
###end p 31
###begin p 32
###xml 68 73 <span type="species:ncbi:9606">human</span>
Increased sensitivity to MMS was also observed in the untransformed human fibroblast lines MRC5 and FD104 after siRNA-mediated reduction of XRCC1 levels (data not shown).
###end p 32
###begin title 33
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
XRCC1-deficient cells display delayed cell-cycle progression following exposure to MMS
###end title 33
###begin p 34
###xml 3 8 3 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 343 351 343 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Figure 3</xref>
###xml 402 403 402 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 577 578 577 578 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 580 581 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 972 973 972 973 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 975 976 975 976 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1229 1234 1229 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1256 1258 1256 1258 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 1363 1364 1363 1364 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1397 1398 1397 1398 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 1400 1401 1400 1401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1514 1519 1514 1519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1569 1574 1569 1574 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
As XRCC1-deficiency has been linked to the perturbation of DNA replication, we next assessed whether reduced XRCC1 levels impacted on cell-cycle progression after DNA damage. Untransfected and siRNA-transfected MDA-MB-453 and MDA-MB-549 cells were exposed to MMS and their cell-cycle distribution analyzed before, 24 and 48 h after treatment (Figure 3). Twenty-four hours post-treatment, MMS causes a G2/M arrest in MDA-MB-549 control cells with unmodulated XRCC1 levels. Fifty percent of these cells accumulate at this stage of the cell cycle, while the fraction of cells in G0/G1 or S phases decreases at this time point. Forty-eight hours after MMS treatment, the cells resume progression through the cell cycle and display an almost identical cell-cycle distribution to that seen before the treatment. In contrast, MDA-MB-549 cells with reduced XRCC1 levels progress through S phase at a significantly reduced rate after MMS-induced DNA damage. While the fraction in G0/G1 decreases, 50% of these cells are found in S phase 24 h after the MMS treatment, suggesting that the limited quantity of XRCC1 leads to a reduced capacity to replicate the genome under DNA damage conditions, which is reminiscent of the observations in XRCC1-deficient CHO cells (23). Forty-eight hours after exposure to MMS, 50% of MDA-MB-549 cells with reduced XRCC1 levels arrest at G2/M, while only 17% are found in G0/G1, indicating that these cells do not resume progression through the cell cycle at this time point. No changes in XRCC1 mRNA levels in response to MMS were observed and XRCC1 transcript levels in XRCC1 siRNA-transfected cells remained constant over the analyzed time (data not shown).
###end p 34
###begin p 35
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 221 222 209 210 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 224 225 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 336 341 324 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 578 583 566 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 718 723 706 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
The MDA-MB-453 cells showed similar, although less marked changes in the cell-cycle profile 24 h after MMS treatment. The number of cells in G2/M increases approximately3-fold while the number of cells in S phase and in G0/G1 decreases when no modulation of XRCC1 protein levels has occurred. Similar to MDA-MB-549 cells, the number of XRCC1-deficient MDA-MB-453 cells in S phase increases 24 h after MMS treatment: 40% of these cells are found in S phase at this time point, which is a 1.8-fold increase compared with untreated cells. Expression analysis by RT-PCR showed that XRCC1 mRNA levels at this time point were not significantly higher than at the time of MMS treatment (data not shown). After 48 h, however, XRCC1 mRNA levels in transfected MDA-MB-453 cells were almost back to normal levels and we could not detect major differences in cell-cycle distribution among the siRNA-transfected and untransfected cells, which resumed an almost normal cell-cycle progression.
###end p 35
###begin title 36
Quantification of intracellular NAD(P)H
###end title 36
###begin p 37
###xml 247 249 247 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 346 347 346 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 412 413 412 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 437 439 437 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 636 638 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 639 641 639 641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 754 763 754 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4A</xref>
###xml 836 841 836 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1509 1514 1509 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1527 1536 1527 1536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Figure 4B</xref>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 811 816 <span type="species:ncbi:9606">human</span>
To confirm the requirement for XRCC1 in damage repair in human cell lines, we investigated additional SSBR endpoints. First, we used a recently described method that indirectly measures the activity of PARP-1 by quantifying intracellular NAD(P)H (38). At the sites of SSB, activated PARP-1 catalyzes the transfer of the ADP-ribose moiety from NAD+ to a number of protein acceptors, resulting in intracellular NAD+ and NAD(P)H depletion (14,44). Translocation of XRCC1 to sites of SSB in HeLa cells has been reported to be dependent on poly(ADP-ribosyl)ation, while this recruitment in turn seems to negatively regulate PARP-1 activity (14,45). We monitored the reduction of intracellular NAD(P)H after a 4 h incubation in the presence or absence of MMS (Figure 4A). In agreement with the findings in CHO cells, human cells with reduced XRCC1 expression responded to MMS exposure with an enhanced reduction of intracellular NAD(P)H. The presence of 3-AB, a specific PARP-inhibitor, almost completely blocked the MMS-induced decrease of NAD(P)H in all tested cells, strongly suggesting that the observed depletion is due to increased PARP-1 activation. No significant differences in cell killing at the MMS concentrations used were noted, implicating that the depletion of NAD(P)H is not due to a reduction in the number of viable cells (data not shown). Nor were these differences in NAD(P)H depletion due to lower levels of PARP-1 protein itself, as PARP-1 levels were similar in cells with normal or ablated XRCC1 expression (Figure 4B).
###end p 37
###begin title 38
Cells lacking XRCC1 display SSBR deficiency
###end title 38
###begin p 39
###xml 481 490 469 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5A</xref>
###xml 650 659 638 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Figure 5B</xref>
###xml 745 750 733 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 996 1001 984 989 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1110 1115 1098 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 952 957 <span type="species:ncbi:9606">human</span>
To confirm the role of XRCC1 in DNA repair in human cells, we next measured SSBR proficiency in individual cells by alkaline single-cell agarose gel electrophoresis. DNA damage was assessed before and immediately after a 1 h exposure of the cells to MMS and after a subsequent 3 h repair incubation in drug-free medium. For both the cell lines MDA-MB-453 and 549, average tail moments immediately after treatment were increased approximately20% in cells with reduced XRCC1 levels (Figure 5A), suggesting that these cells are SSBR defective. This was confirmed during the subsequent repair incubation in drug-free medium. In both cell lines analyzed (Figure 5B), DNA damage persists at higher levels in cells with reduced as compared with normal XRCC1 expression, indicating that DNA repair in these cells is impaired. Thus, we concluded that the presence of XRCC1 after the induction of DNA damage is essential for efficient single-strand resealing in human cells. However, cells with diminished XRCC1 expression were still able to repair DNA, albeit at a reduced rate. This very likely reflects the fact that XRCC1 gene silencing is incomplete but could also suggest the existence of an XRCC1-independent repair mechanism.
###end p 39
###begin title 40
###xml 8 13 8 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
RNAi of XRCC1 expression leads to increased genetic instability
###end title 40
###begin p 41
###xml 14 19 14 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 626 633 626 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 766 771 <span type="species:ncbi:9606">human</span>
A hallmark of XRCC1-deficient CHO cells is their increased levels of spontaneous sister-chromatid exchange rates (19,21). Recently, such cells have also been found to exhibit elevated levels of spontaneous formation of micronuclei (MN) (46). To further assess the effect of altered XRCC1 levels on genetic stability, we counted numbers of binucleated cells with induced MN and total numbers of MN 48 h after MMS treatment. In both MDA-MB-549 and MDA-MB-453 cell lines, siRNA-mediated downregulation of XRCC1 was associated with elevated numbers of binucleated cells with induced MN and increased total numbers of micronuclei (Table 1). These results demonstrate unambiguously that the absence of XRCC1 reduces DNA repair capacity and enhances genetic instability of human cells exposed to DNA damaging agents.
###end p 41
###begin title 42
DISCUSSION
###end title 42
###begin p 43
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 78 81 78 81 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 318 325 318 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 347 352 347 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 441 446 441 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 500 505 500 505 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 930 935 930 935 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1009 1014 1009 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1094 1099 1094 1099 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1099 1102 1099 1102 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 1168 1170 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 170 175 <span type="species:ncbi:4932">yeast</span>
###xml 273 278 <span type="species:ncbi:9606">human</span>
###xml 367 372 <span type="species:ncbi:9606">human</span>
###xml 881 886 <span type="species:ncbi:9606">human</span>
###xml 946 951 <span type="species:ncbi:10090">mouse</span>
###xml 1156 1161 <span type="species:ncbi:10090">mouse</span>
Human XRCC1 has been successfully used for reconstitution experiments in XRCC1-/- CHO cells and for identification of binding partners, e.g. by co-immunoprecipitation or yeast-two hybrid approaches (18). Owing to the lack of mutant cell lines, the role of XRCC1 in SSBR in human cells has not extensively been studied in vivo. We report here that XRCC1-deficiency in human cells recapitulates most, but not all of the phenotypes observed in XRCC1 mutant rodent cells. RNAi-mediated downregulation of XRCC1 resulted in increased sensitivity of three breast cancer cell lines to DNA damaging agents. Hypersensitivity is significant, but least pronounced in the cell line MDA-MB-453, most probably reflecting the fact that XRCC1 levels are typically only reduced to 35% of the normal levels. Nevertheless, these results indicate that XRCC1 might be a rate-limiting factor for SSBR in human cells and are in contrast with findings in XRCC1-deficient mouse cells. Upon transgene-complementation, <10% of wild-type XRCC1 expression levels almost completely rescue the MMS-hypersensitive phenotype of XRCC1-/- cells, suggesting that XRCC1 is not rate limiting in mouse SSBR (22).
###end p 43
###begin p 44
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 29 32 29 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;/&#8722;</sup>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 315 316 315 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 783 788 783 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 829 831 829 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 1591 1592 1591 1592 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 1594 1595 1594 1595 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1706 1707 1706 1707 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1725 1727 1725 1727 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 1804 1805 1804 1805 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2045 2046 2045 2046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1449 1454 <span type="species:ncbi:9606">human</span>
The hypersensitivity of XRCC1-/- CHO cells to DNA damaging agents has been linked to perturbation of DNA replication which leads to a delay of S phase progression. XRCC1-deficient CHO cells accumulate large numbers of SCEs after incorporation of BrdUrd for two consecutive cell cycles and they stop to proliferate (4,23). After the first round of replication, SSBs were found in the halogenated template while nascent DNA, which was copied from this strand, was delayed in maturation as compared with DNA synthesized on an undamaged template. These studies strongly suggested that this delay was due to replication forks encountering SSBs. A different type of perturbation of replication was reported by Kubota and Horiuchi, who observed a decrease in newly fired DNA replication in XRCC1-deficient CHO cells upon MMS treatment (24). This either reflects an unidentified role for XRCC1 in origin firing or an indirect effect due to an increased number or longer persistence of SSBs at replication forks and, as a consequence, a prolonged intra S phase checkpoint. Our experimental set-up for measuring cell-cycle progression is not capable of distinguishing between these different types of perturbations. However, the fact that both MDA-MB-549 and MDA-MB-453 cells with decreased XRCC1 levels progress through S phase considerably more slowly than control cells after MMS treatment strongly suggests that like in rodent cells, XRCC1 is required in human cells to allow unperturbed replication and progression through S phase after DNA damage. We did not detect an accumulation of cells in G0/G1 at any time point, which is in line with observations in CHO cells that XRCC1 function is dispensable during G1 but not S phase (27). After a perturbed S phase, cells with low levels of XRCC1 also arrest at G2/M, indicating that the DNA is still damaged after S phase exit and suggesting that cells are tolerant to a certain degree of damage during S phase progression. This could also explain the rapid progression of control cells to a transient G2/M arrest after MMS treatment, where DNA repair presumably takes place.
###end p 44
###begin p 45
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 396 403 396 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 53 58 <span type="species:ncbi:9606">human</span>
We further demonstrated the imbalance of DNA SSBR in human cells with lowered XRCC1 levels by showing that during exposure to MMS, reduced XRCC1 levels are associated with an increased intracellular NAD(P)H depletion, due to enhanced PARP-1 activity. These results are in agreement with findings in XRCC1-deficient CHO cells and provide further evidence for an involvement of XRCC1 and PARP-1 in in vivo BER following MMS-induced DNA damage. Moreover, they support a role of XRCC1 as a negative regulator of PARP-1 activity. Such a regulatory role has been suggested after overexpression of XRCC1 in HeLa cells, which leads to impaired poly(ADP-ribose) synthesis in response to DNA damage (14). The biological consequences of this inhibition remain to be elucidated.
###end p 45
###begin p 46
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 396 397 396 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 398 400 398 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 404 406 404 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b47">47</xref>
###xml 537 539 537 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b48">48</xref>
###xml 778 783 778 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 934 939 934 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1090 1092 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 1093 1095 1093 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 1099 1101 1099 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 1102 1104 1102 1104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">51</xref>
###xml 1175 1180 1175 1180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 1471 1473 1471 1473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
###xml 1705 1710 1705 1710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 172 177 <span type="species:ncbi:302767">comet</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
###xml 928 933 <span type="species:ncbi:9606">human</span>
We also provide direct proof that XRCC1 is required for DNA strand break resealing by showing that reduced XRCC1 levels partially inhibit DNA rejoining (as measured by the comet assay) and increase MMS-induced micronuclei formation. Again, this is coherent with findings in XRCC1-deficient rodent cells, which display delayed repair kinetics and elevated rates of markers of genetic instability (7,19,22,27,47). Genetic instability as a consequence of DNA repair deficiency is generally regarded as an enabling trait for cancerogenesis (48), and biomarkers of genetic damage such as micronuclei formation are considered to be causally related to early stages of chronic diseases, especially cancer. The involvement of XRCC1 in tumorigenesis is difficult to assess since in mice XRCC1-deficiency results in embryonic lethality. A large number of molecular epidemiological studies have analyzed the impact of polymorphisms in the human XRCC1 gene on cancer risk. Depending on the type of the cancer, these polymorphisms have been reported to be associated with altered cancer predisposition (29,31-34,49-51). One study reported a positive correlation between the presence of a XRCC1 polymorphism and the number of micronuclei in peripheral lymphocytes of individuals that are occupationally exposed to chronic low doses of ionizing radiation, suggesting that XRCC1 might indeed play a role in the maintenance of genetic stability and hence the prevention of tumorigenesis (52). No direct correlation can be drawn between the observations we report here and a putative involvement of XRCC1 in cancer progression. It is nevertheless tempting to speculate that reduced SSBR and genomic instabilities caused by XRCC1-deficiency might facilitate cancer development.
###end p 46
###begin p 47
We thank Norman Moullan and Caroline Fayolle for technical assistance and Dr Alain Puisieux for generously providing certain cell lines. We also thank Dr Marie Fernet for helpful suggestions and Dr Magali Olivier for critical reading of the manuscript. The financial support of 'Electricite de France' and the 'Comite Departemental du Rhone, La Ligue Nationale Contre le Cancer' are gratefully acknowledged. The work of R. Brem was carried out during the tenure of a Special Training Award from the International Agency for Research on Cancer. Funding to pay the Open Access publication charges for this article was provided by the IARC regular budget.
###end p 47
###begin p 48
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 48
###begin title 49
REFERENCES
###end title 49
###begin article-title 50
###xml 74 79 <span type="species:ncbi:9606">human</span>
Excision of C-4'-oxidized deoxyribose lesions from double-stranded DNA by human apurinic/apyrimidinic endonuclease (Ape1 protein) and DNA polymerase beta
###end article-title 50
###begin article-title 51
Instability and decay of the primary structure of DNA
###end article-title 51
###begin article-title 52
Oxidative decay of DNA
###end article-title 52
###begin article-title 53
###xml 129 144 <span type="species:ncbi:10029">Chinese hamster</span>
Incorporated bromodeoxyuridine enhances the sister-chromatid exchange and chromosomal aberration frequencies in an EMS-sensitive Chinese hamster cell line
###end article-title 53
###begin article-title 54
A high yield of translocations parallels the high yield of sister chromatid exchanges in the CHO mutant EM9
###end article-title 54
###begin article-title 55
Hypersensitivity to mutation and sister-chromatid-exchange induction in CHO cell mutants defective in incising DNA containing UV lesions
###end article-title 55
###begin article-title 56
DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines
###end article-title 56
###begin article-title 57
###xml 150 158 150 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro
###end article-title 57
###begin article-title 58
###xml 57 62 <span type="species:ncbi:9606">human</span>
Reconstitution of DNA base excision-repair with purified human proteins: interaction between DNA polymerase beta and the XRCC1 protein
###end article-title 58
###begin article-title 59
Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1
###end article-title 59
###begin article-title 60
XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions
###end article-title 60
###begin article-title 61
###xml 17 22 <span type="species:ncbi:9606">human</span>
XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair
###end article-title 61
###begin article-title 62
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
###end article-title 62
###begin article-title 63
XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage
###end article-title 63
###begin article-title 64
The ataxia-oculomotor apraxia 1 gene product has a role distinct from ATM and interacts with the DNA strand break repair proteins XRCC1 and XRCC4
###end article-title 64
###begin article-title 65
A new XRCC1-containing complex and its role in cellular survival of methyl methanesulfonate treatment
###end article-title 65
###begin article-title 66
###xml 69 74 <span type="species:ncbi:10090">mouse</span>
Requirement for the Xrcc1 DNA base excision repair gene during early mouse development
###end article-title 66
###begin article-title 67
###xml 25 30 <span type="species:ncbi:9606">human</span>
Molecular cloning of the human XRCC1 gene, which corrects defective DNA strand break repair and sister chromatid exchange
###end article-title 67
###begin article-title 68
A CHO-cell strain having hypersensitivity to mutagens, a defect in DNA strand-break repair, and an extraordinary baseline frequency of sister-chromatid exchange
###end article-title 68
###begin article-title 69
Mutations in hamster single-strand break repair gene XRCC1 causing defective DNA repair
###end article-title 69
###begin article-title 70
###xml 2 17 <span type="species:ncbi:10029">Chinese hamster</span>
A Chinese hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges
###end article-title 70
###begin article-title 71
###xml 25 30 <span type="species:ncbi:10090">mouse</span>
Rescue of Xrcc1 knockout mouse embryo lethality by transgene-complementation
###end article-title 71
###begin article-title 72
The relationship between sister-chromatid exchange and perturbations in DNA replication in mutant EM9 and normal CHO cells
###end article-title 72
###begin article-title 73
Independent roles of XRCC1's two BRCT motifs in recovery from methylation damage
###end article-title 73
###begin article-title 74
Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair
###end article-title 74
###begin article-title 75
XRCC1 co-localizes and physically interacts with PCNA
###end article-title 75
###begin article-title 76
A cell cycle-specific requirement for the XRCC1 BRCT II domain during mammalian DNA strand break repair
###end article-title 76
###begin article-title 77
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In situ</italic>
In situ analysis of repair processes for oxidative DNA damage in mammalian cells
###end article-title 77
###begin article-title 78
Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer
###end article-title 78
###begin article-title 79
Pharmacogenetics in cancer treatment
###end article-title 79
###begin article-title 80
Polymorphisms in DNA repair genes and associations with cancer risk
###end article-title 80
###begin article-title 81
Genetic variation in XRCC1, sun exposure, and risk of skin cancer
###end article-title 81
###begin article-title 82
Polymorphisms of DNA repair genes and risk of glioma
###end article-title 82
###begin article-title 83
Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy
###end article-title 83
###begin article-title 84
Gene-environment interactions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk
###end article-title 84
###begin article-title 85
Association of DNA repair gene XRCC1 polymorphisms with head and neck cancer in Korean population
###end article-title 85
###begin article-title 86
###xml 96 104 <span type="species:ncbi:9606">patients</span>
Identification and functional consequences of a novel MRE11 mutation affecting 10 Saudi Arabian patients with the ataxia telangiectasia-like disorder
###end article-title 86
###begin article-title 87
Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time
###end article-title 87
###begin article-title 88
Use of the cytokinesis-block micronucleus assay to measure radiation-induced chromosome damage in lymphoblastoid cell lines
###end article-title 88
###begin article-title 89
###xml 4 9 <span type="species:ncbi:302767">comet</span>
The comet assay: a new method to examine heterogeneity associated with solid tumors
###end article-title 89
###begin article-title 90
A simple technique for quantitation of low levels of DNA damage in individual cells
###end article-title 90
###begin article-title 91
An interaction between the mammalian DNA repair protein XRCC1 and DNA ligase III
###end article-title 91
###begin article-title 92
###xml 53 61 53 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Characterization of the XRCC1-DNA ligase III complex in vitro and its absence from mutant hamster cells
###end article-title 92
###begin article-title 93
The role of poly(ADP-ribosyl)ation
###end article-title 93
###begin article-title 94
###xml 67 72 <span type="species:ncbi:9606">human</span>
Spatial and temporal cellular responses to single-strand breaks in human cells
###end article-title 94
###begin article-title 95
APE1 overexpression in XRCC1-deficient cells complements the defective repair of oxidative single strand breaks but increases genomic instability
###end article-title 95
###begin article-title 96
###xml 120 135 <span type="species:ncbi:10029">Chinese hamster</span>
Molecular analysis of ethyl methanesulfonate-induced mutations at the hprt gene in the ethyl methanesulfonate-sensitive Chinese hamster cell line EM-C11 and its parental line CHO9
###end article-title 96
###begin article-title 97
The hallmarks of cancer
###end article-title 97
###begin article-title 98
Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma
###end article-title 98
###begin article-title 99
A population-based case-control study of the XRCC1 Arg399Gln polymorphism and susceptibility to bladder cancer
###end article-title 99
###begin article-title 100
Polymorphisms of XRCC1 and risk of esophageal and gastric cardia cancer
###end article-title 100
###begin article-title 101
###xml 15 21 <span type="species:ncbi:9606">humans</span>
Micronuclei in humans induced by exposure to low level of ionizing radiation: influence of polymorphisms in DNA repair genes
###end article-title 101
###begin title 102
Figures and Tables
###end title 102
###begin p 103
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 165 166 165 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 214 219 214 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 572 573 572 573 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 585 590 585 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 715 720 711 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 783 788 779 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 100 105 <span type="species:ncbi:9606">human</span>
siRNA targeting the XRCC1 transcript efficiently reduces XRCC1 mRNA and protein levels in the three human breast cancer cell lines MDA-MB-549, MDA-MB-453 and BT20. (A) Cells were transfected with siRNA against the XRCC1 transcript, a scrambled siRNA or untransfected. mRNA (upper panels) and the corresponding protein levels (lower panels) were analyzed 72 h after the start of transfection by quantitative RT-PCR or western blotting, respectively. mRNA and protein levels were calculated by dividing the levels of transfected cells by the levels of untransfected cells. (B) Decreased XRCC1 expression leads to a significant reduction of ligase IIIalpha protein levels in cells transfected with the siRNA targeting XRCC1 (left panel). APE1 protein levels are unaffected by modulated XRCC1 expression (right panel). Proteins were extracted from cell line BT20 72 h after transfection.
###end p 103
###begin p 104
###xml 25 30 25 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
Reduced cell survival of XRCC1-deficient cells after treatment with the DNA damaging agents MMS, hydrogen peroxide or after exposure to ionizing radiation. Cells were treated 72 h after the start of transfection. Survival was assessed 3 days after treatment. All measurements were done in triplicate.
###end p 104
###begin p 105
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
Cell-cycle progression of cells with differential expression of XRCC1. Cells were treated with 100 mug/ml (MDA-MB-453) or 150 mug/ml (MDA-MB-549) MMS for 1 h and reincubated in drug-free medium for 24 and 48 h before cell-cycle distribution was assessed by flow cytometry. Cell-cycle distribution at the time of exposure to MMS was determined in mock-treated cells (0 h).
###end p 105
###begin p 106
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
###xml 91 92 91 92 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 436 437 436 437 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Enhanced depletion of intracellular NAD(P)H levels in cells with reduced XRCC1 expression (A) NAD(P)H depletion was measured after 4 h of MMS treatment either in the presence or in the absence of the PARP-1 inhibitor 3-AB (10 mM). The decrease was calculated by dividing the measured values of MMS-treated cells by the values of mock-treated cells. Measurements were done in triplicate. Shown are the values of one typical experiment. (B) Expression levels of PARP-1 in cells used for the depletion experiments were verified by western blotting of proteins extracted from MDA-MB-549 cells, which were either mock-treated or exposed to 200 mug/ml MMS for 1 h, followed by an incubation in drug-free medium for 3 h.
###end p 106
###begin p 107
###xml 517 518 516 517 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 566 567 565 566 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
Reduced SSBR capacity of cells with decreased XRCC1 levels as assayed by alkaline single-cell gel electrophoresis. siRNA-transfected and untransfected MDA-MB-453 and MDA-MB-549 cells were mock-treated or treated with 100 or 150 mug/ml MMS, respectively, and SSBs (expressed as the tail moment) were quantified before and immediately after the treatment. Cells were also mock-treated or treated with the same concentrations of MMS and subsequently incubated in drug-free medium for 3 h before measuring tail moments. (A) SSBs present immediately after MMS treatment (B) Percentages of MMS-induced SSBs which remain after the 3 h repair incubation (calculated from the tail moment present after the repair incubation).
###end p 107
###begin p 108
###xml 37 42 37 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">XRCC1</italic>
Enhanced induction of micronuclei in XRCC1-deficient cells
###end p 108
###begin p 109
siRNA-transfected or untransfected MDA-MB-453 and MDA-MB-549 cells were treated with 100 or 150 mug/ml MMS, respectively, for 1 h, followed by an incubation in normal medium containing 3 mug/ml cytochalasin B for 48 h before analysis.
###end p 109

